Gate Neurosciences, Inc.

ACTIVE

印第安纳州汉密尔顿县, 印第安纳州, United Stateswww.gateneuro.comHolding11–50 employeesEstablished: 2018-01-01

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2018

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Phase 2

33.3%

Trial Status Distribution

Active, not recruiting

16.7%

Completed

50.0%

Recruiting

16.7%

Terminated

16.7%

Clinical Trials

Trials sponsored by this organization (6)

Pharmacokinetics of Zelquistinel in Fasted or Fed State

Phase 1

Active, not recruiting

interventional

Jul 202532 participants

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Phase 2

Recruiting

interventional

Feb 2025164 participants

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

Phase 1

Completed

interventional

Oct 202240 participants

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

Phase 1

Terminated

interventional

Oct 202018 participants

AGN-241751 in the Treatment of Major Depressive Disorder

Phase 1

Completed

interventional

Nov 2018226 participants

Zelquistinel in the Treatment of Major Depressive Disorder

Phase 2

Completed

interventional

Jun 2018251 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations